Wedbush analyst Yun Zhong has maintained their bullish stance on MNKD stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yun Zhong has given his Buy rating due to a combination of factors related to MannKind’s strategic decisions and product potential. Despite the discontinuation of MNKD-101, the company is advancing with MNKD-102, which is expected to provide better pharmacokinetic exposure and could enter clinical trials by the second half of 2026. This strategic pivot reflects MannKind’s adaptability and focus on leveraging its pipeline for future growth.
Moreover, MannKind’s current commercial product portfolio, including Tyvaso DPI, Furoscix, and Afrezza, continues to show strong growth potential, which supports the company’s valuation. Additionally, the development of MNKD-201 for idiopathic pulmonary fibrosis presents a significant upside opportunity. These factors collectively underpin Yun Zhong’s confidence in MannKind’s future prospects, justifying the Buy rating with a price target adjustment from $11 to $10.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.